Pharmaceuticals

Viral Vector Manufacturing Market Growth Patterns And Forecast Outlook Through 2030

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Viral Vector Manufacturing Market In 2026 And 2030?

The viral vector manufacturing market size has expanded quickly in recent years. It is projected to increase from $8.26 billion in 2025 to $9.9 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 19.9%. Historically, the growth can be ascribed to factors including limited manufacturing capacity, high production cost, reliance on traditional gene delivery methods, regulatory barriers, and fragmented supply chains.

The viral vector manufacturing market size is anticipated to experience substantial growth over the coming years, projected to reach $21.31 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 21.1%. This expansion during the forecast period is driven by factors such as the increasing demand for gene and cell therapies, ongoing advancements in viral vector technology, a surge in R&D investments, the growth of contract manufacturing organizations, and the rising embrace of personalized medicine. Key trends expected in this period include innovation in gene therapy, optimization of viral vector safety, the development of scalable manufacturing processes, enhanced regulatory compliance, and advancements in both upstream and downstream processing.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12398&type=smp

What Key Factors Are Affecting The Viral Vector Manufacturing Market Demand?

The rising occurrence of cancer and infectious diseases is projected to drive the expansion of the viral vector manufacturing market in the coming years. An infectious disease is defined as an ailment caused by a virus or its harmful secretions, transmitted to a vulnerable host through interaction with an infected individual, animal, or object. Cancer encompasses a diverse group of ailments that can emerge in any bodily organ or tissue when abnormal cells proliferate uncontrollably, breaching their normal limits to infiltrate adjacent organs and metastasize to others. Viral vectors are utilized to generate tumor antigens, which are proteins on tumor cells, thereby stimulating the body’s immune system to combat cancer. During pre-clinical and clinical investigations, viral vectors have been employed as immunizations for numerous infectious conditions. For example, data from July 2024, provided by the Australian Institute of Health and Welfare, an Australia-based government agency, revealed that in Australia, cancer diagnoses climbed from 160,570 in 2022 to 164,694 in 2023, showing a significant annual increase, a pattern that underscores the increasing incidence of cancer in the nation. Additionally, in August 2024, figures released by the UK Health Security Agency, a UK-based executive agency, indicated that in England, the UK Health Security Agency (UKHSA) documented 368 measles cases in 2023, representing an almost sevenfold increase from the 53 cases recorded in 2022, with 44% of cases originating in the West Midlands and 33% in London. Consequently, the rising occurrence of both cancer and infectious diseases is fueling the expansion of the viral vector manufacturing market.

How Is Segmentation Applied In The Viral Vector Manufacturing Market Segment Analysis?

The viral vector manufacturing market covered in this report is segmented –

1) By Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Other Types

2) By Disease: Cancer, Genetic Disorders, Infectious Diseases, Other Diseases

3) By Workflow: Upstream Processing, Downstream Processing

4) By Application: Gene And Cell Therapy Development, Vaccine Development, Biopharmaceutical And Pharmaceutical Discovery, Biomedical Research

5) By End-User: Research Organizations, Biotech And Pharmaceutical Companies, Other End Users

Subsegments:

1) By Adenoviral Vectors: Serotype 5, Serotype 2, Serotype 26

2) By Adeno-Associated Viral Vectors: AAV2, AAV5, AAV8, AAV9, Others

3) By Lentiviral Vectors: HIV-1-Based Lentiviral Vectors, SIV-Based Lentiviral Vectors, Others

4) By Retroviral Vectors: Moloney Murine Leukemia Virus (MoMLV), Gammaretroviral Vectors, Others

5) By Other Types: Sendai Viral Vectors, Vesicular Stomatitis Virus (VSV)-Based Vectors, Measles Virus Vectors, Others

Which Trends Are Impacting The Progress Of The Viral Vector Manufacturing Market?

Leading companies in the viral vector manufacturing market are concentrating on developing advanced products, such as viral vector platforms specifically designed for viral vector production and manufacturing. Viral vector platforms are comprehensive systems tailored for the efficient production and processing of viral vectors, essential for applications including gene therapy and vaccine development. For instance, in May 2023, AGC Biologics, a US-based global biopharmaceutical contract development and manufacturing organization (CDMO), launched its BravoAAV and ProntoLVV platforms. These platforms are engineered to provide flexible and accelerated vector development and manufacturing for cell and gene therapy programs, offering GMP product delivery within nine months. They are backed by a global regulatory and supply network and in-house plasmid DNA services. With custom processes, templated material approaches, and prequalified analytical methods, these platforms significantly contribute to the viral vector manufacturing market’s projected growth, reaching $5.5 billion by 2035, by addressing the increasing demand for efficient development and delivery of life-changing gene therapies and vaccines.

Who Are The Companies Participating In The Viral Vector Manufacturing Market Environment?

Major companies operating in the viral vector manufacturing market are Sanofi S.A., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC, Oxford Biomedica plc, LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV

Get The Full Viral Vector Manufacturing Market Report:

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Which Region Accounts For The Largest Portion Of The Viral Vector Manufacturing Market?

North America was the largest region in the viral vector manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Viral Vector Manufacturing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Browse Through More Reports Similar to the Global Viral Vector Manufacturing Market 2026, By The Business Research Company

Viral Vector Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Viral And Non Viral Vector Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-and-non-viral-vector-manufacturing-global-market-report

Oral Expectorant Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795